Journal of Genetic Counseling

, Volume 26, Issue 1, pp 79–92 | Cite as

Adherence to Recommended Risk Management among Unaffected Women with a BRCA Mutation

  • Adam H. Buchanan
  • Corrine I. Voils
  • Joellen M. Schildkraut
  • Catherine Fine
  • Nora K. Horick
  • P. Kelly Marcom
  • Kristi Wiggins
  • Celette Sugg Skinner
Original Research

Abstract

Identifying unaffected women with a BRCA mutation can have a significant individual and population health impact on morbidity and mortality if these women adhere to guidelines for managing cancer risk. But, little is known about whether such women are adherent to current guidelines. We conducted telephone surveys of 97 unaffected BRCA mutation carriers who had genetic counseling at least one year prior to the survey to assess adherence to current guidelines, factors associated with adherence, and common reasons for performing and not performing recommended risk management. More than half of participants reported being adherent with current risk management recommendations for breast cancer (69 %, n = 67), ovarian cancer (82 %, n = 74) and both cancers (66 %, n = 64). Older age (OR = 10.53, p = 0.001), white race (OR = 8.93, p = 0.019), higher breast cancer genetics knowledge (OR = 1.67, p = 0.030), higher cancer-specific distress (OR = 1.07, p = 0.002) and higher physical functioning (OR = 1.09, p = 0.009) were significantly associated with adherence to recommended risk management for both cancers. Responses to open-ended questions about reasons for performing and not performing risk management behaviors indicated that participants recognized the clinical utility of these behaviors. Younger individuals and those with lower physical functioning may require targeted interventions to improve adherence, perhaps in the setting of long-term follow-up at a multi-disciplinary hereditary cancer clinic.

Keywords

BRCA1 gene BRCA2 gene Genetic counseling Breast cancer Ovarian cancer 

References

  1. American Society of Clinical Oncology (2003). American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. Journal of Clinical Oncology, 21(12), 2397–2406. doi:10.1200/jco.2003.03.189.CrossRefGoogle Scholar
  2. Berliner, J. L., Fay, A. M., & Practice Issues Subcommittee of the National Society of Genetic Counselors’ Familial Cancer Risk Counseling Special Interest, G (2007). Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of genetic counselors. Journal of Genetic Counseling, 16(3), 241–260.CrossRefPubMedGoogle Scholar
  3. Berliner, J. L., Fay, A. M., Cummings, S. A., Burnett, B., & Tillmanns, T. (2013). NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer. Journal of Genetic Counseling, 22(2), 155–163.CrossRefPubMedGoogle Scholar
  4. Botkin, J. R., Smith, K. R., Croyle, R. T., Baty, B. J., Wylie, J. E., Dutson, D., et al. (2003). Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet Part A, 118(3), 201–209.CrossRefGoogle Scholar
  5. Bradbury, A. R., Ibe, C. N., Dignam, J. J., Cummings, S. A., Verp, M., White, M. A., et al. (2008). Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. Genetics in Medicine, 10(3), 161–166.CrossRefPubMedPubMedCentralGoogle Scholar
  6. Buchanan, A. H., Skinner, C. E., Calingaert, B., Schildkraut, J. M., King, R. H., & Marcom, P. K. (2009). Cancer genetic counseling in rural North Carolina oncology clinics: program establishment and patient characteristics. Commun Oncol(6), 70–77.Google Scholar
  7. Burke, W., Daly, M., Garber, J., Botkin, J., Kahn, M. J., Lynch, P., et al. (1997). Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer genetics studies consortium. JAMA, 277(12), 997–1003.CrossRefPubMedGoogle Scholar
  8. Caiata-Zufferey, M., & Pagani, O. (2015). Challenges in managing genetic cancer risk: a long-term qualitative study of unaffected women carrying BRCA1/BRCA2 mutations. Genetics in Medicine, 17(9), 726–732. doi:10.1038/gim.2014.183.CrossRefPubMedGoogle Scholar
  9. Calzone, K. A., Prindiville, S. A., Jourkiv, O., Jenkins, J., DeCarvalho, M., Wallerstedt, D. B., et al. (2005). Randomized comparison of group versus individual genetic education and counseling for familial breast and/or ovarian cancer. Journal of Clinical Oncology, 23(15), 3455–3464.CrossRefPubMedGoogle Scholar
  10. Caplan, L. S., McQueen, D. V., Qualters, J. R., Leff, M., Garrett, C., & Calonge, N. (2003). Validity of women’s self-reports of cancer screening test utilization in a managed care population. Cancer Epidemiology, Biomarkers & Prevention, 12(11 Pt 1), 1182–1187.Google Scholar
  11. CDC. (2014, September 8, 2014). Office of Public Health Genomics - Genomic Tests and Family History by Levels of Evidence. Retrieved April 28, 2015, from http://www.cdc.gov/genomics/gtesting/tier.htm
  12. Chagpar, A. B., Polk Jr., H. C., & McMasters, K. M. (2008). Racial trends in mammography rates: a population-based study. Surgery, 144(3), 467–472.CrossRefPubMedGoogle Scholar
  13. Chen, S., & Parmigiani, G. (2007). Meta-analysis of BRCA1 and BRCA2 penetrance. Journal of Clinical Oncology, 25(11), 1329–1333.CrossRefPubMedPubMedCentralGoogle Scholar
  14. Claes, E., Evers-Kiebooms, G., Decruyenaere, M., Denayer, L., Boogaerts, A., Philippe, K., et al. (2005). Surveillance behavior and prophylactic surgery after predictive testing for hereditary breast/ovarian cancer. Behavioral Medicine, 31(3), 93–105.CrossRefPubMedGoogle Scholar
  15. Finch, A., Beiner, M., Lubinski, J., Lynch, H. T., Moller, P., Rosen, B., et al. (2006). Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA, 296(2), 185–192.CrossRefPubMedGoogle Scholar
  16. Finch, A. P., Lubinski, J., Moller, P., Singer, C. F., Karlan, B., Senter, L., et al. (2014). Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. Journal of Clinical Oncology, 32(15), 1547–1553.CrossRefPubMedPubMedCentralGoogle Scholar
  17. Friebel, T. M., Domchek, S. M., Neuhausen, S. L., Wagner, T., Evans, D. G., Isaacs, C., et al. (2007). Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. Clinical Breast Cancer, 7(11), 875–882.CrossRefPubMedGoogle Scholar
  18. Garcia, C., Wendt, J., Lyon, L., Jones, J., Littell, R. D., Armstrong, M. A., et al. (2014). Risk management options elected by women after testing positive for a BRCA mutation. Gynecologic Oncology, 132(2), 428–433.CrossRefPubMedGoogle Scholar
  19. Hadley, D. W., Jenkins, J. F., Dimond, E., de Carvalho, M., Kirsch, I., & Palmer, C. G. (2004). Colon Cancer screening practices after genetic counseling and testing for hereditary nonpolyposis colorectal cancer. Journal of Clinical Oncology, 22(1), 39–44.CrossRefPubMedGoogle Scholar
  20. Harris, P. A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009). Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. Journal of Biomedical Informatics, 42(2), 377–381.CrossRefPubMedGoogle Scholar
  21. Horowitz, M. J., Wilner, N., & Alvarez, W. (1979). Impact of event scale: a measure of subjective stress. Psychosomatic Medicine, 41(3), 209–218.CrossRefPubMedGoogle Scholar
  22. Hsieh, H. F., & Shannon, S. E. (2005). Three approaches to qualitative content analysis. Qualitative Health Research, 15(9), 1277–1288.CrossRefPubMedGoogle Scholar
  23. Hughes, C., Lerman, C., Schwartz, M., Peshkin, B., Wenzel, L., Narod, S., et al. (2002). All in the family: evaluation of the processand content of sisters’ communication about BRCA1 and BRCA2 genetic test results. American Journal of Medical Genetics, 107, 143–150.CrossRefPubMedGoogle Scholar
  24. Julian-Reynier, C., Bouhnik, A. D., Mouret-Fourme, E., Gauthier-Villars, M., Berthet, P., Lasset, C., et al. (2010). Time to prophylactic surgery in BRCA1/2 carriers depends on psychological and other characteristics. Genetics in Medicine, 12(12), 801–807.CrossRefPubMedGoogle Scholar
  25. Khoury, M. J., Coates, R. J., & Evans, J. P. (2010). Evidence-based classification of recommendations on use of genomic tests in clinical practice: dealing with insufficient evidence. Genetics in Medicine, 12(11), 680–683.CrossRefPubMedGoogle Scholar
  26. King, E. S., Rimer, B. K., Trock, B., Balshem, A., & Engstrom, P. (1990). How valid are mammography self-reports? American Journal of Public Health, 80(11), 1386–1388.CrossRefPubMedPubMedCentralGoogle Scholar
  27. Kinney, A. Y., Simonsen, S. E., Baty, B. J., Mandal, D., Neuhausen, S. L., Seggar, K., et al. (2006). Risk reduction behaviors and provider communication following genetic counseling and BRCA1 mutation testing in an African American kindred. Journal of Genetic Counseling, 15(4), 293–305.CrossRefPubMedGoogle Scholar
  28. Kurian, A. W., Sigal, B. M., & Plevritis, S. K. (2010). Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. Journal of Clinical Oncology, 28(2), 222–231.CrossRefPubMedGoogle Scholar
  29. Leonarczyk, T. J., & Mawn, B. E. (2015). Cancer risk management decision making for BRCA+ women. Western Journal of Nursing Research, 37(1), 66–84.CrossRefPubMedGoogle Scholar
  30. Lerman, C., Hughes, C., Croyle, R. T., Main, D., Durham, C., Snyder, C., et al. (2000). Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Preventive Medicine, 31(1), 75–80.CrossRefPubMedGoogle Scholar
  31. Lodder, L. N., Frets, P. G., Trijsburg, R. W., Meijers-Heijboer, E. J., Klijn, J. G., Seynaeve, C., et al. (2002). One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery). Breast Cancer Research and Treatment, 73(2), 97–112.CrossRefPubMedGoogle Scholar
  32. Meijers-Heijboer, E. J., Verhoog, L. C., Brekelmans, C. T., Seynaeve, C., Tilanus-Linthorst, M. M., Wagner, A., et al. (2000). Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet, 355(9220), 2015–2020.CrossRefPubMedGoogle Scholar
  33. Meijers-Heijboer, H., Brekelmans, C. T., Menke-Pluymers, M., Seynaeve, C., Baalbergen, A., Burger, C., et al. (2003). Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. Journal of Clinical Oncology, 21(9), 1675–1681.CrossRefPubMedGoogle Scholar
  34. Metcalfe, K. A., Birenbaum-Carmeli, D., Lubinski, J., Gronwald, J., Lynch, H., Moller, P., et al. (2008). International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. International Journal of Cancer, 122(9), 2017–2022.CrossRefPubMedPubMedCentralGoogle Scholar
  35. Miranda, P. Y., Tarraf, W., & Gonzalez, H. M. (2011). Breast cancer screening and ethnicity in the United States: implications for health disparities research. Breast Cancer Research and Treatment, 128(2), 535–542.CrossRefPubMedGoogle Scholar
  36. Montano, D. E., & Phillips, W. R. (1995). Cancer screening by primary care physicians: a comparison of rates obtained from physician self-report, patient survey, and chart audit. American Journal of Public Health, 85(6), 795–800.CrossRefPubMedPubMedCentralGoogle Scholar
  37. NCCN. (2000, 06/01/00). NCCN Practice Guidelines: Genetics/Familial High-Risk Cancer Screening. Retrieved February 11, 2011, from http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf
  38. NCCN. (2001, 04/19/01). Clinical Practice Guidelines in Oncology - Genetic/Familial High-Risk Screening: Breast Version 1.2001. Retrieved February 11, 2011, from http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf
  39. NCCN. (2002, 04/22/02). Clinical Practice Guidelines in Oncology - Genetic/Familial High-Risk Assessment: Breast Version 1.2002. Retrieved February 11, 2011, from http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf
  40. NCCN. (2005, 09/09/05). Clinical Practice Guidelines in Oncology - Genetic/Familial High-Risk Assessment: Breast and Ovarian Version 1.2005. Retrieved February 11, 2011, from http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf
  41. NCCN. (2006, 12/14/05). Clinical Practice Guidelines in Oncology - Genetic/Familial High-Risk Assessment: Breast and Ovarian Version 1.2006. Retrieved February 11, 2011, from http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf
  42. NCCN. (2010, 03/08/10). Clinical Practice Guidelines in Oncology - Genetic/Familial High-Risk Assessment: Breast and Ovarian Version 1.2010. Retrieved February 11, 2011, from http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf
  43. NCCN. (2012, 05/02/12). Clinical Practice Guidelines in Oncology - Genetic/Familial High-Risk Assessment: Breast and Ovarian Version 1.2012. RetrievedNCCN August 16, 2012, from http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf
  44. NCCN. (2003, 07/28/03). Clinical Practice Guidelines in Oncology - Genetic/Familial High-Risk Assessment: Breast and Ovarian Version 1.2003. Retrieved February, 2011, from http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf
  45. NCCN. (2015, 3/30/15). Clinical Practice Guidelines in Oncology - Genetic/Familial High-Risk Assessment: Breast and Ovarian Version 1.2015. Retrieved April 30, 2015, from http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf
  46. O’Neill, S. C., Valdimarsdottir, H. B., Demarco, T. A., Peshkin, B. N., Graves, K. D., Brown, K., et al. (2010). BRCA1/2 test results impact risk management attitudes, intentions, and uptake. Breast Cancer Research and Treatment, 124(3), 755–764.CrossRefPubMedPubMedCentralGoogle Scholar
  47. Onwuegbuzie, A. (2003). Effect sizes in qualitative research: a prolegomenon. Quality & Quantity, 37(4), 393–409.CrossRefGoogle Scholar
  48. Pal, T., Lee, J. H., Besharat, A., Thompson, Z., Monteiro, A. N., Phelan, C., et al. (2014). Modes of delivery of genetic testing services and the uptake of cancer risk management strategies in BRCA1 and BRCA2 carriers. Clinical Genetics, 85(1), 49–53.CrossRefPubMedGoogle Scholar
  49. Patenaude, A. F., Dorval, M., DiGianni, L. S., Schneider, K. A., Chittenden, A., & Garber, J. E. (2006). Sharing BRCA1/2 test results with first-degree relatives: factors predicting who women tell. Journal of Clinical Oncology, 24(4), 700–706.CrossRefPubMedGoogle Scholar
  50. Peshkin, B. N., Schwartz, M. D., Isaacs, C., Hughes, C., Main, D., & Lerman, C. (2002). Utilization of breast cancer screening in a clinically based sample of women after BRCA1/2 testing. Cancer Epidemiology, Biomarkers & Prevention, 11(10 Pt 1), 1115–1118.Google Scholar
  51. Petrucelli, N., Daly, M. B., & Feldman, G. L. (2013). BRCA1 and BRCA2 hereditary breast and ovarian cancer. In R. A. Pagon, M. P. Adam, H. H. Ardinger, S. E. Wallace, A. Amemiya, L. J. H. Bean, T. D. Bird, C. T. Fong, R. J. H. Smith & K. Stephens (Eds.), GeneReviews(R). Seattle (WA): University of Washington, Seattle University of Washington, Seattle. All rights reserved.Google Scholar
  52. Phillips, K. A., Jenkins, M. A., Lindeman, G. J., McLachlan, S. A., McKinley, J. M., Weideman, P. C., kConFab, I. (2006). Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Clinical Genetics, 70(3), 198–206.Google Scholar
  53. Rauscher, G. H., Johnson, T. P., Cho, Y. I., & Walk, J. A. (2008). Accuracy of self-reported cancer-screening histories: a meta-analysis. Cancer Epidemiology, Biomarkers & Prevention, 17(4), 748–757.CrossRefGoogle Scholar
  54. Rebbeck, T. R., Friebel, T., Lynch, H. T., Neuhausen, S. L., van ‘t Veer, L., Garber, J. E., Weber, B. L. (2004). Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. Journal of Clinical Oncology, 22(6), 1055–1062.Google Scholar
  55. Rebbeck, T. R., Kauff, N. D., & Domchek, S. M. (2009). Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. Journal of the National Cancer Institute, 101(2), 80–87.CrossRefPubMedPubMedCentralGoogle Scholar
  56. Riley, B. D., Culver, J. O., Skrzynia, C., Senter, L. A., Peters, J. A., Costalas, J. W., et al. (2012). Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of genetic counselors. Journal of Genetic Counseling, 21(2), 151–161.CrossRefPubMedGoogle Scholar
  57. Robson, M. E., Storm, C. D., Weitzel, J., Wollins, D. S., Offit, K., & American Society of Clinical Oncology (2009). American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. Journal of Clinical Oncology, 28(5), 893–901..CrossRefGoogle Scholar
  58. Scheuer, L., Kauff, N., Robson, M., Kelly, B., Barakat, R., Satagopan, J., et al. (2002). Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. Journal of Clinical Oncology, 20(5), 1260–1268.CrossRefPubMedGoogle Scholar
  59. Schmeler, K. M., Sun, C. C., Bodurka, D. C., White, K. G., Soliman, P. T., Uyei, A. R.,. Lu, K. H. (2006). Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations. Obstetrics and Gynecology, 108(3 Pt 1), 515–520.CrossRefPubMedGoogle Scholar
  60. Schwartz, M. D., Isaacs, C., Graves, K. D., Poggi, E., Peshkin, B. N., Gell, C., et al. (2012). Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance. Cancer, 118(2), 510–517.CrossRefPubMedGoogle Scholar
  61. Schwartz, M. D., Kaufman, E., Peshkin, B. N., Isaacs, C., Hughes, C., DeMarco, T., et al. (2003). Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing. Journal of Clinical Oncology, 21(21), 4034–4041.CrossRefPubMedGoogle Scholar
  62. Schwartz, M. D., Lerman, C., Brogan, B., Peshkin, B. N., Halbert, C. H., DeMarco, T., et al. (2004). Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. Journal of Clinical Oncology, 22(10), 1823–1829.CrossRefPubMedGoogle Scholar
  63. Sidon, L., Ingham, S., Clancy, T., Clayton, R., Clarke, A., Jones, E. A., et al. (2012). Uptake of risk-reducing salpingo-oophorectomy in women carrying a BRCA1 or BRCA2 mutation: evidence for lower uptake in women affected by breast cancer and older women. British Journal of Cancer, 106(4), 775–779.CrossRefPubMedGoogle Scholar
  64. Skinner, C., Rawl, S., Moser, B., Buchanan, A., Scott, L., Champion, V., et al. (2005). Impact of the cancer risk intake system on patient-clinician discussions of tamoxifen, genetic counseling, and colonoscopy. Journal of General Internal Medicine, 20(4), 360–365.CrossRefPubMedGoogle Scholar
  65. Skinner, C. S., Buchanan, A., Champion, V., Monahan, P., Rawl, S., Springston, J., et al. (2011). Process outcomes from a randomized controlled trial comparing tailored mammography interventions delivered via telephone vs. DVD. Patient Educ Couns, 85(2), 308–312.CrossRefPubMedGoogle Scholar
  66. Skinner, C. S., Tiro, J., & Champion, V. L. (2015). The health belief model. In K. Glanz, B. K. Rimer, & K. Viswanath (Eds.), Health Behavior Theory, Research, and Practice (5th ed., pp. 75–94). San Francisco, CA: Jossey-Bass.Google Scholar
  67. Spielberger, C. D., Gorsuch, R., Lushene, R., & al., e. (1983). State-Trait Anxiety Inventory for Adults: Sampler Set - Manual, Test, Scoring Key. Palo Alto, CA: Mind Garden.Google Scholar
  68. Tinley, S. T., Houfek, J., Watson, P., Wenzel, L., Clark, M. B., Coughlin, S., et al. (2004). Screening adherence in BRCA1/2 families is associated with primary physicians’ behavior. American Journal of Medical Genetics. Part A, 125A(1), 5–11.CrossRefPubMedGoogle Scholar
  69. Trepanier, A., Ahrens, M., McKinnon, W., Peters, J., Stopfer, J., Grumet, S. C., et al. (2004). Genetic cancer risk assessment and counseling: recommendations of the National Society of genetic counselors. Journal of Genetic Counseling, 13(2), 83–114.CrossRefPubMedGoogle Scholar
  70. Uyei, A., Peterson, S. K., Erlichman, J., Broglio, K., Yekell, S., Schmeler, K.,. Arun, B. (2006). Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Cancer, 107(12), 2745–2751.CrossRefPubMedGoogle Scholar
  71. Ware Jr., J., Kosinski, M., & Keller, S. D. (1996). A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Medical Care, 34(3), 220–233.CrossRefPubMedGoogle Scholar
  72. Warner, E., Hill, K., Causer, P., Plewes, D., Jong, R., Yaffe, M., et al. (2011). Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. Journal of Clinical Oncology, 29(13), 1664–1669.CrossRefPubMedPubMedCentralGoogle Scholar
  73. Watson, M., Kash, K. M., Homewood, J., Ebbs, S., Murday, V., & Eeles, R. (2005). Does genetic counseling have any impact on management of breast cancer risk? Genetic Testing, 9(2), 167–174.CrossRefPubMedGoogle Scholar
  74. Willis, G. B. (2005). Cognitive interviewing. Thousand Oaks, CA: SAGE Publications.CrossRefGoogle Scholar
  75. Yerkes, R. M., & Dodson, J. D. (1908). The relation of strength of stimulus to rapidity of habit-formation. Journal of Comparative Neurology and Psychology, 18, 459–482.CrossRefGoogle Scholar
  76. Zapka, J. G., Bigelow, C., Hurley, T., Ford, L. D., Egelhofer, J., Cloud, W. M., et al. (1996). Mammography use among sociodemographically diverse women: the accuracy of self-report. American Journal of Public Health, 86(7), 1016–1021.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© National Society of Genetic Counselors, Inc. 2016

Authors and Affiliations

  • Adam H. Buchanan
    • 1
  • Corrine I. Voils
    • 2
    • 3
  • Joellen M. Schildkraut
    • 4
  • Catherine Fine
    • 5
  • Nora K. Horick
    • 6
  • P. Kelly Marcom
    • 3
    • 4
  • Kristi Wiggins
    • 7
  • Celette Sugg Skinner
    • 8
  1. 1.Geisinger Health SystemGenomic Medicine InstituteDanvilleUSA
  2. 2.Center for Health Services Research in Primary CareDurham VA Medical CenterDurhamUSA
  3. 3.Department of MedicineDuke University Medical CenterDurhamUSA
  4. 4.Duke Cancer InstituteDuke University Medical CenterDurhamUSA
  5. 5.Department of GeneticsUNC Lineberger Comprehensive Cancer CenterChapel HillUSA
  6. 6.Massachusetts General Hospital Biostatistics CenterBostonUSA
  7. 7.Division of Cellular TherapyDuke University Medical CenterDurhamUSA
  8. 8.Department of Clinical Sciences and Harold C Simmons Cancer CenterUniversity of Texas – SouthwesternDallasUSA

Personalised recommendations